A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Trial ID or NCT#
Status
Purpose
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.
Official Title
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Eligibility Criteria
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Mariel Rojas
1 650-723-0530
View on ClinicalTrials.gov